{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:27:15Z","timestamp":1791833235436,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of this study is to investigate the clinical significance and risk factors of upgrading in the International Society of Urological Pathology (ISUP) Grade Group System in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 583 patients diagnosed with prostate cancer by systematic biopsy were treated with RARP without neoadjuvant therapy from November 2011 to December 2018. Clinicopathological data were obtained from our clinical records. ISUP grade upgrading (IGU) was defined as \u2018ISUP grade in prostatectomy specimen determined to be higher than that in the biopsy specimen\u2019. Clinicopathological factors, including age, PSA, prostate volume at biopsy (PV), PSA density, clinical stage, body mass index (BMI), interval from biopsy to prostatectomy, maximum percentage of cancer involvement per core (%CI), total number of biopsy cores, percentage of cancer positive biopsy cores (%PC), and sampling density were analyzed to detect potential risk factors of IGU. Biochemical recurrence (BCR) rates were calculated to analyze the effect of IGU on cancer prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In univariate analysis, BMI was a positive predictor of IGU, while %CI, %PC, and sampling density were negative predictors of IGU. BMI and %PC were statistically significant predictors of IGU in multivariate analysis. For cases diagnosed as ISUP grade group 2 or higher at biopsy, there was a significant difference in BCR rates between cases with and without IGU.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results from our cohort showed that elements of both high-grade cancer risk (such as BMI) and sampling efficiency (such as %PC) contribute to IGU. Excluding cases diagnosed as ISUP grade group 1 at biopsy, BCR-free rates were significantly worse in cases with IGU, highlighting the need for more accurate pathological diagnosis at biopsy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08248-y","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T22:02:52Z","timestamp":1620165772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuta","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kakutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hakozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"8248_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"8248_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374. https:\/\/doi.org\/10.1001\/jama.280.11.969.","journal-title":"JAMA"},{"issue":"2","key":"8248_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad LL, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244\u201352. https:\/\/doi.org\/10.1097\/PAS.0000000000000530.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"8248_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.eururo.2015.11.036","volume":"69","author":"S Loeb","year":"2016","unstructured":"Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69(6):1135\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.036.","journal-title":"Eur Urol"},{"issue":"10","key":"8248_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/bjc.2016.86","volume":"114","author":"DM Berney","year":"2016","unstructured":"Berney DM, Beltran L, Fisher G, et al. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. Br J Cancer. 2016;114(10):1078\u201383. https:\/\/doi.org\/10.1038\/bjc.2016.86.","journal-title":"Br J Cancer"},{"issue":"6","key":"8248_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/1097-0215(20001220)90:6<305::AID-IJC1>3.0.CO;2-U","volume":"90","author":"CR King","year":"2000","unstructured":"King CR. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer. 2000;90(6):305\u201311. https:\/\/doi.org\/10.1002\/1097-0215(20001220)90:6<305::AID-IJC1>3.0.CO;2-U.","journal-title":"Int J Cancer"},{"key":"8248_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1442-2042.2002.00456.x","volume":"9","author":"K Cam","year":"2002","unstructured":"Cam K, Yucel S, Turkeri L, Akdas A. Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens. Int J Urol. 2002;9:252\u201360.","journal-title":"Int J Urol"},{"issue":"5","key":"8248_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.050.","journal-title":"Eur Urol"},{"issue":"8b","key":"8248_CR9","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1111\/j.1464-410X.2011.10119.x","volume":"108","author":"NM Corcoran","year":"2011","unstructured":"Corcoran NM, Hong MK, Casey RG, et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 2011;108(8b):E202\u201310. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10119.x.","journal-title":"BJU Int"},{"issue":"3","key":"8248_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/luts.12181","volume":"10","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, et al. Predictors of early continence after robot-assisted radical prostatectomy. Low Urin Tract Symptoms. 2018;10(3):287\u201391. https:\/\/doi.org\/10.1111\/luts.12181.","journal-title":"Low Urin Tract Symptoms"},{"key":"8248_CR11","doi-asserted-by":"publisher","first-page":"e0234113","DOI":"10.1371\/journal.pone.0234113","volume":"15","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Teshima T, Fujimura T, et al. Comparison of perioperative outcomes in elderly (age\u226575years) vs. younger men undergoing robot-assisted radical prostatectomy. PLoS ONE. 2020;15:e0234113.","journal-title":"PLoS ONE"},{"key":"8248_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.juro.2006.09.025","volume":"177","author":"FK Chun","year":"2007","unstructured":"Chun FK, Briganti A, Graefen M, et al. Development and external validation of an extended repeat biopsy nomogram. J Urol. 2007;177:510\u20135.","journal-title":"J Urol"},{"issue":"6","key":"8248_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.juro.2011.07.104","volume":"186","author":"JD Davies","year":"2011","unstructured":"Davies JD, Aghazadeh, Phillips S, et al. Prostate size as a predictor of Gleason score upgrade in patients with low risk prostate cancer. J Urol. 2011;186(6):2221\u20137. https:\/\/doi.org\/10.1016\/j.juro.2011.07.104.","journal-title":"J Urol"},{"key":"8248_CR14","doi-asserted-by":"publisher","unstructured":"Park J, Yoo S, Cho MC, et al. The impact of pathologic upgrading of Gleason score 7 prostate cancer on the risk of the biochemical recurrence after radical prostatectomy. Biomed Res Int. 2018;4510149.\u00a0https:\/\/doi.org\/10.1155\/2018\/4510149.","DOI":"10.1155\/2018\/4510149"},{"issue":"16","key":"8248_CR15","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/pros.23905","volume":"79","author":"WS Jang","year":"2019","unstructured":"Jang WS, Koh DH, Kim J, Lee JS, Chung DY, Ham WS, et al. The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer. Prostate. 2019;79(16):1805\u201310. https:\/\/doi.org\/10.1002\/pros.23905.","journal-title":"Prostate"},{"issue":"1","key":"8248_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12957-018-1433-3","volume":"16","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wu B, Zha Z, Zhao H, Jiang Y, Yuan J. Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies. World J Surg Oncol. 2018;16(1):124. https:\/\/doi.org\/10.1186\/s12957-018-1433-3.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"8248_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.juro.2013.09.034","volume":"191","author":"A Vellekoop","year":"2014","unstructured":"Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol. 2014;191(2):350\u20137. https:\/\/doi.org\/10.1016\/j.juro.2013.09.034.","journal-title":"J Urol"},{"issue":"22","key":"8248_CR18","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1002\/cncr.28303","volume":"119","author":"M Truong","year":"2013","unstructured":"Truong M, Slezak JA, Chee PL, et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013;119(22):3992\u20134002. https:\/\/doi.org\/10.1002\/cncr.28303.","journal-title":"Cancer"},{"issue":"2","key":"8248_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","volume":"194","author":"KT Dinh","year":"2015","unstructured":"Dinh KT, Mahal BA, Zieher DR, et al. Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low risk prostate cancer. J Urol. 2015;194(2):343\u20139. https:\/\/doi.org\/10.1016\/j.juro.2015.02.015.","journal-title":"J Urol"},{"issue":"1","key":"8248_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12894-019-0526-9","volume":"19","author":"N Bullock","year":"2019","unstructured":"Bullock N, Simpkin A, Fowler S, Varma M, Kynaston H, Narahari K. Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urol. 2019;19(1):94. https:\/\/doi.org\/10.1186\/s12894-019-0526-9.","journal-title":"BMC Urol"},{"issue":"2","key":"8248_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/21681805.2013.829519","volume":"48","author":"E Suer","year":"2014","unstructured":"Suer E, Gokce MI, Gulpinar O, Gucal Guclu A, Haciyev P, Gogus C, et al. How significant is upgrade in Gleason score between prostate biopsy and radical prostatectomy pathology while discussing less invasive treatment options? Scand J Urol. 2014;48(2):177\u201382. https:\/\/doi.org\/10.3109\/21681805.2013.829519.","journal-title":"Scand J Urol"},{"issue":"4","key":"8248_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prnil.2016.07.004","volume":"4","author":"SM Evans","year":"2016","unstructured":"Evans SM, Bandarage VP, Kronborg C, et al. Gleason group concordance between biopsy and radical prostatectomy specimens: a cohort study from prostate Cancer outcome registry- Victoria. Prostate Int. 2016;4(4):145\u201351. https:\/\/doi.org\/10.1016\/j.prnil.2016.07.004.","journal-title":"Prostate Int"},{"issue":"5","key":"8248_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","volume":"63","author":"EH Allott","year":"2013","unstructured":"Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2012.11.013.","journal-title":"Eur Urol"},{"issue":"3","key":"8248_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1210\/jc.2005-1326","volume":"91","author":"V Kupelian","year":"2006","unstructured":"Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91(3):843\u201350. https:\/\/doi.org\/10.1210\/jc.2005-1326.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"8248_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/pcan.2015.44","volume":"18","author":"A Pichon","year":"2015","unstructured":"Pichon A, Neuzillet Y, Botto H, Raynaud JP, Radulescu C, Molini\u00e9 V, et al. Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. Prostate Cancer Prostatic Dis. 2015;18(4):382\u20137. https:\/\/doi.org\/10.1038\/pcan.2015.44.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"8248_CR26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0022-5347(05)00162-X","volume":"175","author":"SJ Freedland","year":"2006","unstructured":"Freedland SJ, Platz EA, Presti JC, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175(2):500\u20134. https:\/\/doi.org\/10.1016\/S0022-5347(05)00162-X.","journal-title":"J Urol"},{"issue":"5","key":"8248_CR27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.juro.2015.11.068","volume":"195","author":"T Kimura","year":"2016","unstructured":"Kimura T, Takahashi H, Okayasu M, Kido M, Inaba H, Kuruma H, et al. Time trends in histological features of latent prostate Cancer in Japan. J Urol. 2016;195(5):1415\u201320. https:\/\/doi.org\/10.1016\/j.juro.2015.11.068.","journal-title":"J Urol"},{"key":"8248_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1464-410X.2011.10187.x","volume":"109","author":"C Thomas","year":"2011","unstructured":"Thomas C, Pfirrmann K, Pieles F, et al. Predictors for clinically relevant Gleason score upgrading in patients undergoing radical prostatectomy. BJU Int. 2011;109:214\u20139.","journal-title":"BJU Int"},{"issue":"6","key":"8248_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00345-014-1348-8","volume":"33","author":"T Seisen","year":"2015","unstructured":"Seisen T, Roudot-Thoraval F, Bosset PO, Beaugerie A, Allory Y, Vordos D, et al. Predicting the risk of harbouring high-grade disease for patients diagnosed with prostate cancer scored as Gleason \u22646 on biopsy cores. World J Urol. 2015;33(6):787\u201392. https:\/\/doi.org\/10.1007\/s00345-014-1348-8.","journal-title":"World J Urol"},{"issue":"6","key":"8248_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/1097-0215(20001220)90:6<326::AID-IJC3>3.0.CO;2-J","volume":"90","author":"CR King","year":"2000","unstructured":"King CR, Long JP. Prostate biopsy grading errors: A sampling problem? Int J Cancer (Radiat Oncol Invest). 2000;90(6):326\u201330. https:\/\/doi.org\/10.1002\/1097-0215(20001220)90:6<326::AID-IJC3>3.0.CO;2-J.","journal-title":"Int J Cancer (Radiat Oncol Invest)"},{"key":"8248_CR31","first-page":"4285","volume":"36","author":"V Zugor","year":"2016","unstructured":"Zugor V, Poth S, Kuhn R, et al. Is an extended prostate biopsy scheme associated with an improvement in the accuracy between the biopsy Gleason score and radical prostatectomy pathology? A multivariate analysis. Anticancer Res. 2016;36:4285\u20138.","journal-title":"Anticancer Res"},{"issue":"6","key":"8248_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00345-014-1371-9","volume":"33","author":"LO Reis","year":"2015","unstructured":"Reis LO, Sanches BC, de Mendon\u00e7a GB, et al. Gleason underestimation is predicted by prostate biopsy core length. World J Urol. 2015;33(6):821\u20136. https:\/\/doi.org\/10.1007\/s00345-014-1371-9.","journal-title":"World J Urol"},{"issue":"5","key":"8248_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2013.05.059","volume":"64","author":"MM Siddiqui","year":"2013","unstructured":"Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, et al. Magnetic resonance imaging\/ ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2013.05.059.","journal-title":"Eur Urol"},{"issue":"11","key":"8248_CR34","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00432-015-1991-5","volume":"141","author":"C Arsov","year":"2015","unstructured":"Arsov C, Becker N, Rabenalt R, Hiester A, Quentin M, Dietzel F, et al. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol. 2015;141(11):2061\u20138. https:\/\/doi.org\/10.1007\/s00432-015-1991-5.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"8248_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.euo.2019.08.001","volume":"3","author":"S Goel","year":"2020","unstructured":"Goel S, Shoag JE, Gross MD, al Hussein al Awamlh B, Robinson B, Khani F, et al. Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(1):10\u201320. https:\/\/doi.org\/10.1016\/j.euo.2019.08.001.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"8248_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.23736\/S0393-2249.19.03367-8","volume":"72","author":"S De Luca","year":"2020","unstructured":"De Luca S, Fiori C, Bollito E, et al. Risk of Gleason score 3+4=7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy. Minerva Urol Nefrol. 2020;72(3):360\u20138. https:\/\/doi.org\/10.23736\/S0393-2249.19.03367-8.","journal-title":"Minerva Urol Nefrol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08248-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08248-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08248-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T22:02:56Z","timestamp":1620165776000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08248-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8248"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08248-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided a written informed consent. This study, including permission for all use of clinicopathological data pertaining to subjects, was in accordance with the Helsinki declaration and was approved by the institutional review board of the Tokyo University Hospital (approval no. 3124).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"501"}}